Whether you're sourcing suppliers or finding providers, start your journey with confidence today.
Exenatide (GLP-1 Receptor Agonist)
Also known as: Byetta, Bydureon, Exendin-4
Confidence
Updated 2026-03-18
Exenatide is a synthetic form of exendin-4, a peptide originally isolated from Gila monster venom, and was the first GLP-1 receptor agonist approved by the FDA. Available as twice-daily (Byetta) and once-weekly (Bydureon) formulations, it established the GLP-1 agonist class as a cornerstone of diabetes management.
Class
GLP-1 Receptor Agonist
Routes
Subcutaneous
Half-Life
Byetta (IR): ~2.4 hours | Bydureon (ER): ~2 weeks (due to microsphere release)
Exenatide shares ~53% homology with human GLP-1 and activates the GLP-1 receptor with similar potency. It stimulates glucose-dependent insulin secretion, suppresses inappropriately elevated glucagon, slows gastric emptying, and reduces food intake. Resistance to DPP-4 degradation extends its duration of action compared to native GLP-1.
Half-Life
Byetta (IR): ~2.4 hours | Bydureon (ER): ~2 weeks (due to microsphere release)
Bioavailability
Subcutaneous: ~65–75%
Type 2 diabetes mellitus as adjunct to diet and exercise. Used in combination with metformin, sulfonylureas, thiazolidinediones, or basal insulin.
Studied in DURATION Phase III program. EXSCEL cardiovascular outcomes trial (14,752 patients) showed non-inferiority for MACE but did not meet superiority. HbA1c reductions of 0.8–1.5%. Moderate weight loss of 2–4 kg. Long post-marketing safety record since 2005.
Human Studies
100
Animal Studies
80
Common: nausea (especially early in treatment), vomiting, diarrhea. Rare: pancreatitis, renal impairment (especially with dehydration from GI effects), injection site reactions (nodules with Bydureon). Black box warning for medullary thyroid carcinoma in rodents.
FDA-approved since 2005. The original GLP-1 agonist. Prescribing has declined with availability of semaglutide and tirzepatide, but retains a role as an established, lower-cost option.
Drug Interactions: May slow absorption of oral medications. Enhanced hypoglycemia risk with insulin/sulfonylureas. Monitoring: Renal function (especially if GI side effects cause dehydration), A1C, lipase/amylase. Research Gaps: Less cardiovascular benefit data compared to liraglutide or semaglutide.
Subcutaneous (Byetta)
Common Range
5–10 mcg
Timing
Within 60 minutes before morning and evening meals
Frequency
Twice daily
Cycling
Start 5mcg BID for 1 month, then increase to 10mcg BID based on tolerability
Storage
Refrigerated before first use; room temperature up to 30 days
Important Note
Must be given before meals. Bydureon (ER): 2mg once weekly, any time, without regard to meals.
Connect with a verified provider offering Exenatide therapy near you.
GLP-1 Receptor Agonist
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for type 2 diabetes and chronic weight management. It represents the leading edge of the incretin-based therapy revolution and has become one of the most widely prescribed peptide therapeutics globally. Available in both injectable (Ozempic, Wegovy) and oral (Rybelsus) formulations.
GLP-1 Receptor Agonist
Liraglutide is a GLP-1 receptor agonist FDA-approved for type 2 diabetes (Victoza) and chronic weight management (Saxenda). As an acylated GLP-1 analog with 97% homology to native GLP-1, it was one of the first once-daily GLP-1 agonists to gain widespread clinical adoption and paved the way for longer-acting agents like semaglutide.
Dual GIP/GLP-1 Receptor Agonist
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management. It represents a novel dual-incretin approach that has demonstrated superior weight loss and glycemic control compared to selective GLP-1 agonists in multiple Phase III trials.
Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Always consult with a licensed healthcare provider before starting, stopping, or modifying any peptide therapy. PeptideSupplierMatch does not prescribe, sell, or distribute peptides.
Whether you're sourcing peptides for your business or looking for providers near you, we can help.